Program
HICM-188
A development code. Also written as “HiCM-188 therapy”, “HiCM-188 Cells” and “HiCM-188 Chitosan Patch”.
Its studies are mostly in Heart Failure, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HELP Therapeutics | 33 open or running | phase 3since Mar 16, 2026 | Jan 15, 2024 | Jun 30, 2027phase 3 · NCT07496372 |
| HELP Therapeutics | 11 open or running | phase 2since Jun 9, 2026 | Jun 9, 2026 | Feb 2028phase 2 · NCT07646210 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2024First study: phase 2 study in Heart FailureNew to HELP TherapeuticsHELP Therapeutics · NCT06340048 · 36 enrolled · China
- Mar 10, 2026Phase 2 study in Ischemic Heart FailureHELP Therapeutics · NCT07471698 · 16 planned · China
- Mar 16, 2026Phase 3 study in Heart FailurePhase 3 reachedHELP Therapeutics · NCT07496372 · 80 planned · China
- Jun 9, 2026HELP Therapeutics's first study: phase 2 study in Advanced Heart FailureNew to HELP TherapeuticsHELP Therapeutics · NCT07646210 · 12 planned · United States
Ahead
- Nov 10, 2026Primary completion: phase 2 study in Heart FailureHELP Therapeutics · NCT06340048
- Jun 30, 2027Primary completion: phase 3 study in Heart FailureHELP Therapeutics · NCT07496372
- Feb 2028Primary completion: phase 2 study in Advanced Heart FailureHELP Therapeutics · NCT07646210
- Oct 20, 2028Primary completion: phase 2 study in Ischemic Heart FailureHELP Therapeutics · NCT07471698
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07646210Advanced Heart Failure · United States | 2 | Not yet recruiting | HELP Therapeutics | Feb 2028 | 12 |
| NCT07496372Heart Failure · China | 3 | Recruiting | HELP Therapeutics | Jun 30, 2027 | 80 |
| NCT07471698Ischemic Heart Failure · China | 2 | Not yet recruiting | HELP Therapeutics | Oct 20, 2028 | 16 |
| NCT06340048Heart Failure · China | 2 | Active, not recruiting | HELP Therapeutics | Nov 10, 2026 | 36 |
How it is read
Names in the registry
- “HiCM-188 therapy”, 2 entries
- “HiCM-188 Cells”, 1 entry
- “HiCM-188 Chitosan Patch”, 1 entry
Codes read as this program: HICM188.
Conditions, from the studies’ own filings
- Heart Failure, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.